Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Real World Analysis from a Single Center

Valcyte (valganciclovir) - Roche, Tanabe Pharma

Prevymis (letermovir) - Merck (MSD)

M. Jorgenson 1; J. Descourouez 1; G. Leverson 2; W. Rose 2; A. Beyer 3; D. Al-Adra 2

Jun 17, 2026